PH12019502417A1 - Method of determining expression level ot t315i variant of abl1 - Google Patents

Method of determining expression level ot t315i variant of abl1

Info

Publication number
PH12019502417A1
PH12019502417A1 PH12019502417A PH12019502417A PH12019502417A1 PH 12019502417 A1 PH12019502417 A1 PH 12019502417A1 PH 12019502417 A PH12019502417 A PH 12019502417A PH 12019502417 A PH12019502417 A PH 12019502417A PH 12019502417 A1 PH12019502417 A1 PH 12019502417A1
Authority
PH
Philippines
Prior art keywords
abl1
primer
reverse
expression level
variant
Prior art date
Application number
PH12019502417A
Inventor
Kiyonori Katsuragi
Hideaki Tanaka
Ryuta Ito
Daisuke Koga
Original Assignee
Otsuka Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceuticals Co Ltd filed Critical Otsuka Pharmaceuticals Co Ltd
Publication of PH12019502417A1 publication Critical patent/PH12019502417A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)

Abstract

This disclosure provides a method that contains (1) a step for reverse transcribing a target RNA specimen in the presence of a modified nucleic acid having a base sequence complementary to a region that contains the T315I mutation position of wild-type ABL1 mRNA, using, in the same container, (a) a reverse primer that binds to a region downstream from the T315I mutation position of ABL1 mRNA and (b) a reverse primer that binds to a region upstream from the T315I mutation position of ABL1 mRNA, and (2) a step for determining the expression level of the ABL1 T315I mutation on the basis of the ratio of the reverse transcription product due to the primer (a) with respect to the reverse transcription product due to the primer (b). This disclosure also provides a kit for this method.
PH12019502417A 2017-04-26 2019-10-25 Method of determining expression level ot t315i variant of abl1 PH12019502417A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017087578 2017-04-26
PCT/JP2018/016748 WO2018199136A1 (en) 2017-04-26 2018-04-25 Method for measuring expression level of abl1 t315i mutation

Publications (1)

Publication Number Publication Date
PH12019502417A1 true PH12019502417A1 (en) 2020-10-19

Family

ID=63919184

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019502417A PH12019502417A1 (en) 2017-04-26 2019-10-25 Method of determining expression level ot t315i variant of abl1

Country Status (6)

Country Link
JP (1) JPWO2018199136A1 (en)
KR (1) KR20200002933A (en)
CN (1) CN110997938A (en)
PH (1) PH12019502417A1 (en)
SG (2) SG10201912849TA (en)
WO (1) WO2018199136A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111321200A (en) * 2020-02-28 2020-06-23 广州安镝声生物医药科技有限公司 Extracellular ABL1 kinase activity detection kit and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211483A1 (en) * 2002-05-09 2003-11-13 Schroeder Benjamin G. Methods for the enrichment of low-abundance polynucleotides
JP5221248B2 (en) * 2008-08-26 2013-06-26 株式会社日立ハイテクノロジーズ Method for preparing a cDNA library with a reduced content of cDNA clones derived from highly expressed genes
TWI541507B (en) * 2009-09-11 2016-07-11 香港中文大學 Methods for assessing liver pathologies
KR101875199B1 (en) * 2010-11-11 2018-07-06 주식회사 파나진 Methods and kits for the detection of BCR-ABL fusion gene mutant using PNA mediated Real-time PCR clamping
CN102676638B (en) * 2011-03-08 2014-06-04 苏州大学附属第一医院 Method and kit for detecting drug-resistance mutation site of ABL kinase domain of BCR/ABL fusion gene
JP6531312B2 (en) * 2014-10-17 2019-06-19 東洋鋼鈑株式会社 Method for detecting BCR-ABL inhibitor resistance related mutation and data acquisition method for predicting BCR-ABL inhibitor resistance using the same
CN105349681A (en) * 2015-12-07 2016-02-24 湖南圣维基因科技有限公司 BCR-ABL fusion gene T315I mutation fluorescent PCR detection kit
RU2609641C1 (en) * 2015-12-07 2017-02-02 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Method of analysis of somatic mutations in the bcr/abl chimeric gene using rt-pcr and subsequent hybridization with oligonucleotide biological microchip (biochip)
CN105441568B (en) * 2016-01-06 2019-01-08 武汉海吉力生物科技有限公司 For detecting primer, probe and the kit of mankind BCR-ABL fusion T315I mutation

Also Published As

Publication number Publication date
KR20200002933A (en) 2020-01-08
SG10201912849TA (en) 2020-02-27
WO2018199136A1 (en) 2018-11-01
CN110997938A (en) 2020-04-10
JPWO2018199136A1 (en) 2020-05-14
SG11201909983QA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
GB2568608A (en) Personalized genetic testing
EP4328322A3 (en) Probe library construction
WO2015119941A3 (en) Genome fractioning
MX2019002093A (en) Methods for the detection of genomic copy changes in dna samples.
BR112016014022A2 (en) anti-cd3 antibodies, isolated nucleic acid, vector, host cell, anti-cd3 antibody production method, immunoconjugate, composition, use of anti-cd3 antibody, treatment methods, methods of enhancing immune function and kit
AU2016409886A1 (en) Intelligent list reading
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
MX2016016902A (en) Methods of analyzing nucleic acids from individual cells or cell populations.
MY182904A (en) Calculator and method for determining phase correction data for an audio signal
RS53880B1 (en) Adam6 mice
EP4269610A3 (en) Probe and method for detecting transcript resulting from fusion gene and/or exon skipping
MX2022001085A (en) Humanized anti-c1s antibodies and methods of use thereof.
MX2016006745A (en) Method and apparatus for determining associated user.
MX2018012550A (en) Compositions and methods for the detection of host cell proteins.
EP3215150A4 (en) Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
NZ730124A (en) A method of predicting risk of recurrence of cancer
WO2018126278A3 (en) Methods to distinguish rna and dna in a combined preparation
EA201891628A1 (en) INHIBITION OF ALLERGIC REACTIONS USING IL-33 INHIBITOR
MX2018005448A (en) Methods for apolipoprotein detection.
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
BR112022012731A2 (en) ANTI-OX40 ANTIBODY AND USE OF IT
PH12019502417A1 (en) Method of determining expression level ot t315i variant of abl1
WO2011100752A3 (en) Methods and materials for assessing rna expression